Distinguished in Lung Adenocarcinoma

Dr. Christina S. Baik

Oncology | Hematology Oncology
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Lung Adenocarcinoma
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christina Baik is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Baik is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Baik is currently accepting new patients.

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 2 clinical trials in the study of Lung Adenocarcinoma.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MA
Languages Spoken
English
Castilian
Hindi
Korean
Punjabi
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
325 9th Ave, Seattle, WA 98104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Ramucirumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Enrollment Status: Terminated
Publish Date: June 28, 2023
Intervention Type: Drug
Study Drug: Tarloxotinib bromide
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug, Other
Study Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)
A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

72 Total Publications

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Similar Doctors
Distinguished in Lung Adenocarcinoma
Dr. Keith D. Eaton
Oncology
Distinguished in Lung Adenocarcinoma
Dr. Keith D. Eaton
Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, Filipino, French, Hindi, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Eaton is an Oncologist in Seattle, Washington. Dr. Eaton is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Salivary Gland Tumors, and Small Cell Lung Cancer (SCLC). Dr. Eaton is currently accepting new patients.

Joseph Rosales
Distinguished in Lung Adenocarcinoma
Dr. Joseph Rosales
Oncology | Hematology
Distinguished in Lung Adenocarcinoma
Dr. Joseph Rosales
Oncology | Hematology

Franciscan Oncology At St. Joseph

1617 South J Street, 
Tacoma, WA 
 (27.1 miles away)
253-426-4297
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

"Joseph Rosales, MD, has been a physician for over 20 years and a hematologist-oncologist in Western Washington since 2011 -- in Seattle, Federal Way and Tacoma. He is experienced in general hematology and oncology, with specialties in breast and thoracic oncology. Dr. Rosales considers himself a guide in his patients’ therapeutic journey. He meets his patients wherever they are - physically and emotionally - and strives to provide them the knowledge and perspective required to navigate difficult decisions in their care. His treatment philosophy has been consistent: to make sure that the patient remains in as much control of their care as possible while getting the best care possible.Dr. Rosales also maintains activity within the community, including involvement in oncologic education and advocacy. He received the2022 Binaytara Foundation for Excellence in Cancer Care ""Rising Star in Health Equity"" awardfor his demonstration of excellent leadership in improving cancer care in underprivileged communities.Multidisciplinary Lung Cancer Treatment during Covid-19 Video". Dr. Rosales is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration.

Distinguished in Lung Adenocarcinoma
Dr. Siddhartha Devarakonda
Hematology | Oncology
Distinguished in Lung Adenocarcinoma
Dr. Siddhartha Devarakonda
Hematology | Oncology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
 (1.2 miles away)
206-386-2424
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siddhartha Devarakonda is a Hematologist and an Oncologist in Seattle, Washington. Dr. Devarakonda has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baik's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile